NCT02924584View on ClinicalTrials.gov

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

February 28, 2017

Study Completion Date

April 30, 2018

Conditions
ER/PR(+), Her2(-) Breast Cancer
Trial Locations (1)

Unknown

National Cheng Kung University, Tainan City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02924584 - Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan | Biotech Hunter | Biotech Hunter